Route 92 Medical Gains EU and MDSAP Certification for its Neurovascular Stroke-Intervention-Focused Product Portfolio
November 20, 2024 08:00 ET
|
Route 92 Medical, Inc.
Route 92 Medical announces EU and MDSAP certification for its neurovascular stroke-intervention-focused product portfolio.
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
November 20, 2024 07:55 ET
|
ZyVersa Therapeutics
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
Route 92 Medical Announces $50 Million Series F Extension Equity Financing
September 23, 2024 09:00 ET
|
Route 92 Medical, Inc.
Route 92 Medical announces $50 million series F extension equity financing to support its commercial expansion.
Pharmazz Inc. announces that Dr. Neil Marwah has joined the Company as its President
September 11, 2024 07:00 ET
|
Pharmazz, Inc.
Pharmazz Inc. announces that Dr. Neil Marwah has joined the Company as its President.
Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.
August 21, 2024 07:00 ET
|
Pharmazz, Inc.
Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.
Bioxodes annonce la recommandation positive du DMC pour son essai de phase 2a dans le traitement des AVC hémorragiques avec BIOX-101
August 21, 2024 02:30 ET
|
Bioxodes
Le Comité de surveillance des données (DMC, Data Monitoring Committee) a recommandé la poursuite de l’étude après l’examen planifié des données provenant des 8 premiers patients L’analyse des...
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
August 21, 2024 02:30 ET
|
Bioxodes
Planned Data Monitoring Committee (DMC) meeting recommended continuation of the study after reviewing data from the first 8 patients Interim data from 16 patients scheduled around the end of 2024 ...
Bioxodes franchit une première étape dans le recrutement de patients pour son essai de phase 2a dans le traitement des hémorragies intracérébrales avec BIOX-101
June 27, 2024 02:30 ET
|
Bioxodes
Candidat médicament « first-in-class » évalué chez les huit premiers patients Gosselies (Belgique), le 27 juin 2024 – Bioxodes SA, société biopharmaceutique en phase clinique développant de...
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke
June 27, 2024 02:30 ET
|
Bioxodes
First-in-class drug candidate evaluated in first eight patients Gosselies (Belgium), June 27, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for...
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of healthcare AI
June 25, 2024 09:00 ET
|
Qure.ai Technologies Limited
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of healthcare AI.